Incident hepatocellular carcinoma in patients with type 2 diabetes
(Comparison between propensity−score matched cohorts: Combinations vs monotherapy)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)	# of cases (overall risk) (Comparison cohort)		HR (95% CI)
GLP−1RA(+)DRUG(+) vs DRUG(+)GLP−1RA(−)						
91,421	GLP−1RA(+)Insulin(+)	Insulin(+)GLP−1RA(−)	278 (0.30%)	307 (0.34%)		0.79 (0.67−0.93)
77,794	GLP−1RA(+)Metformin(+)	Metformin(+)GLP−1RA(−)	164 (0.21%)	189 (0.24%)		0.80 (0.65−0.98)
23,646	GLP−1RA(+)DDP−4(+)	DPP−4(+)GLP−1RA(−)	62 (0.26%)	66 (0.28%)		0.81 (0.57−1.14)
41,689	GLP−1RA(+)SGLT2(+)	SGLT2(+)GLP−1RA(−)	85 (0.20%)	88 (0.21%)		0.77 (0.58−1.04)
46,620	GLP−1RA(+)SU(+)	SU(+)GLP−1RA(−)	105 (0.23%)	112 (0.24%)		0.83 (0.64−1.08)
17,763	GLP−1RA(+)TZD(+)	TZD(+)GLP−1RA(−)	24 (0.14%)	27 (0.15%)		0.77 (0.45−1.34)
GLP−1RA(+)DRUG(+) vs GLP−1RA(+)DRUG(−)						
44,939	GLP−1RA(+)Insulin(+)	GLP−1RA(+)Insulin(−)	108 (0.24%)	28 (0.06%)		3.36 (2.22−5.10)
44,617	GLP−1RA(+)Metformin(+)	GLP−1RA(+)Metformin(−)	132 (0.30%)	125 (0.28%)		0.92 (0.72−1.17)
32,119	GLP−1RA(+)DDP−4(+)	GLP−1RA(+)DPP−4(−)	72 (0.22%)	58 (0.18%)		1.15 (0.81−1.63)
59,969	GLP−1RA(+)SGLT2(+)	GLP−1RA(+)SGLT2(−)	113 (0.19%)	136 (0.23%)		0.71 (0.56−0.91)
49,408	GLP−1RA(+)SU(+)	GLP−1RA(+)SU(−)	112 (0.23%)	94 (0.19%)		1.08 (0.82−1.42)
19,297	GLP−1RA(+)TZD(+)	GLP−1RA(+)TZD(−)	25 (0.13%)	46 (0.24%)		0.51 (0.31−0.83)

Hazard Ratio (HR): 0.20 0.30 0.40 0.60 0.80 2.0 3.00 4.0